论文部分内容阅读
目的探讨吡格列酮与厄贝沙坦联合治疗早期2型糖尿病肾病的临床疗效。方法选取2010年6月～2011年6月某院收治的糖尿病肾病患者90例,按随机数字表法分为观察组和对照组。对照组给予吡格列酮,观察组在对照组基础上加用厄贝沙坦。3个月后观察两组临床疗效、血糖及肾功能指标变化。结果观察组总有效率为89.9%(40/45),对照组为66.7%(30/45),差异有统计学意义(P﹤0.05);治疗后两组血糖指标[HbA1C、FPG、PBG2h]及肾功能指标[SCr、BUN、UAER、mAlb]水平均显著下降(P﹤0.05),观察组较对照组下降更为显著(P﹤0.05);两组用药前后肝肾功能未见明显异常,均未出现明显不良反应。结论吡格列酮与厄贝沙坦联合治疗早期2型糖尿病肾病能起到协同作用,显著提高疗效,降低血糖,改善肾功能,值得临床推广和探讨。
Objective To investigate the clinical efficacy of pioglitazone combined with irbesartan in the treatment of early type 2 diabetic nephropathy. Methods Ninety patients with diabetic nephropathy admitted in a hospital from June 2010 to June 2011 were divided into observation group and control group according to random number table. The control group was given pioglitazone. The observation group was given irbesartan on the basis of the control group. Three months later, the clinical curative effect, blood glucose and renal function indexes were observed. Results The total effective rate was 89.9% (40/45) in the observation group and 66.7% (30/45) in the control group, the difference was statistically significant (P <0.05). After treatment, the blood glucose level [HbA1C, FPG, PBG2h] (P <0.05). The levels of SCr, BUN, UAER and mAlb in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in the liver and kidney function between the two groups before and after treatment, No obvious adverse reactions. Conclusion The combination of pioglitazone and irbesartan in the treatment of early type 2 diabetic nephropathy can play a synergistic effect, significantly improve the curative effect, lower blood sugar and improve renal function, worthy of clinical promotion and discussion.